Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.22
DSCO's Cash to Debt is ranked lower than
77% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. DSCO: 1.22 )
Ranked among companies with meaningful Cash to Debt only.
DSCO' s 10-Year Cash to Debt Range
Min: 0.42  Med: 4.97 Max: No Debt
Current: 1.22
Equity to Asset -0.11
DSCO's Equity to Asset is ranked lower than
94% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. DSCO: -0.11 )
Ranked among companies with meaningful Equity to Asset only.
DSCO' s 10-Year Equity to Asset Range
Min: -0.11  Med: 0.67 Max: 0.93
Current: -0.11
-0.11
0.93
F-Score: 4
Z-Score: -30.26
M-Score: 0.42
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -2183.26
DSCO's Operating margin (%) is ranked lower than
84% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. DSCO: -2183.26 )
Ranked among companies with meaningful Operating margin (%) only.
DSCO' s 10-Year Operating margin (%) Range
Min: -619900  Med: -2635.96 Max: -834.65
Current: -2183.26
-619900
-834.65
Net-margin (%) -2299.65
DSCO's Net-margin (%) is ranked lower than
84% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. DSCO: -2299.65 )
Ranked among companies with meaningful Net-margin (%) only.
DSCO' s 10-Year Net-margin (%) Range
Min: -920000  Med: -2792.70 Max: -850.13
Current: -2299.65
-920000
-850.13
ROE (%) -246.81
DSCO's ROE (%) is ranked lower than
92% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. DSCO: -246.81 )
Ranked among companies with meaningful ROE (%) only.
DSCO' s 10-Year ROE (%) Range
Min: -575.17  Med: -157.32 Max: -65.45
Current: -246.81
-575.17
-65.45
ROA (%) -94.09
DSCO's ROA (%) is ranked lower than
83% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. DSCO: -94.09 )
Ranked among companies with meaningful ROA (%) only.
DSCO' s 10-Year ROA (%) Range
Min: -186.83  Med: -101.89 Max: -56.04
Current: -94.09
-186.83
-56.04
ROC (Joel Greenblatt) (%) -2390.43
DSCO's ROC (Joel Greenblatt) (%) is ranked lower than
72% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. DSCO: -2390.43 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
DSCO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2578.49  Med: -1340.74 Max: -199.97
Current: -2390.43
-2578.49
-199.97
EBITDA Growth (3Y)(%) -19.70
DSCO's EBITDA Growth (3Y)(%) is ranked lower than
69% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. DSCO: -19.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
DSCO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -55  Med: -26.30 Max: 22.5
Current: -19.7
-55
22.5
EPS Growth (3Y)(%) -17.60
DSCO's EPS Growth (3Y)(%) is ranked lower than
64% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. DSCO: -17.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
DSCO' s 10-Year EPS Growth (3Y)(%) Range
Min: -61.7  Med: -21.20 Max: 25.5
Current: -17.6
-61.7
25.5
» DSCO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

DSCO Guru Trades in Q2 2013

Jim Simons 12,392 sh (New)
» More
Q3 2013

DSCO Guru Trades in Q3 2013

Jim Simons Sold Out
» More
Q1 2014

DSCO Guru Trades in Q1 2014

George Soros 166,400 sh (New)
» More
Q2 2014

DSCO Guru Trades in Q2 2014

George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with DSCO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 21.00
DSCO's P/S is ranked lower than
66% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. DSCO: 21.00 )
Ranked among companies with meaningful P/S only.
DSCO' s 10-Year P/S Range
Min: 19.17  Med: 253.00 Max: 5370
Current: 21
19.17
5370
Current Ratio 2.73
DSCO's Current Ratio is ranked lower than
65% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. DSCO: 2.73 )
Ranked among companies with meaningful Current Ratio only.
DSCO' s 10-Year Current Ratio Range
Min: 0.84  Med: 4.25 Max: 19
Current: 2.73
0.84
19
Quick Ratio 2.73
DSCO's Quick Ratio is ranked lower than
62% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. DSCO: 2.73 )
Ranked among companies with meaningful Quick Ratio only.
DSCO' s 10-Year Quick Ratio Range
Min: 0.84  Med: 3.91 Max: 19
Current: 2.73
0.84
19
Days Inventory 23.13
DSCO's Days Inventory is ranked higher than
88% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 122.55 vs. DSCO: 23.13 )
Ranked among companies with meaningful Days Inventory only.
DSCO' s 10-Year Days Inventory Range
Min: 9.5  Med: 853.15 Max: 2464.8
Current: 23.13
9.5
2464.8

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.08
DSCO's Price/Median PS Value is ranked higher than
98% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. DSCO: 0.08 )
Ranked among companies with meaningful Price/Median PS Value only.
DSCO' s 10-Year Price/Median PS Value Range
Min: 0.01  Med: 0.29 Max: 14.43
Current: 0.08
0.01
14.43
Earnings Yield (Greenblatt) (%) -98.00
DSCO's Earnings Yield (Greenblatt) (%) is ranked lower than
96% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. DSCO: -98.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DSCO' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 180.7  Med: 297.20 Max: 1813985.5
Current: -98
180.7
1813985.5

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 7 18 34
EPS($) -0.42 -0.30 -0.15
EPS without NRI($) -0.42 -0.30 -0.15

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:DYBN.Germany,
Discovery Laboratories Inc was incorporated as a Delaware corporation in 1992. The Company is a specialty biotechnology company engaged in creating life-saving products for critical-care patients with respiratory disease and improving the standard of care in pulmonary medicine. Its proprietary drug technology produces a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to pulmonary surfactant, a substance produced naturally in the lung and essential for normal respiratory function and survival. The Company is developing its KL4 surfactant in liquid, lyophilized and aerosolized dosage forms. IT is also developing novel drug delivery technologies potentially to enable efficient delivery of its aerosolized KL4 surfactant. The Company is initially engaged in improving the management of respiratory distress syndrome (RDS) in premature infants. It has developed a disposable aerosol-conducting airway connector for infants that is intended to simplify the delivery of aerosolized medications and other inhaled therapies to critical-care patients requiring ventilatory support. The Company has exclusive rights to its CAG technology for use with pulmonary surfactants for all respiratory diseases and conditions. In addition, it hold in the U.S. exclusive rights to the CAG technology for use with certain non-surfactant drugs to treat various pediatric and adult respiratory indications in hospitals and other health care institutions. It has also developed a novel, disposable aerosol-conducting airway connector that is intended to simplify the delivery of aerosolized medications, including its aerosolized KL4 surfactant, and inhaled therapies to infants requiring ventilatory support in the NICU and PICU. AEROSURF, AFECTAIR, AFECTAIR DUO, DISCOVERYLABS, SURFAXIN, SURFAXIN LS, and WARMING CRADLE are the Company's registered and common law trademarks. The Company's development, manufacture, distribution, marketing and advertising of drug, device, and combination drug-device products are subject to extensive regulation by federal, state and local governmental authorities in the U.S., including the FDA, and by similar agencies in other countries.
» More Articles for DSCO

Headlines

Articles On GuruFocus.com
Discovery Laboratories Inc. Reports Operating Results (10-Q) Nov 15 2010 
Discovery Laboratories Inc. Reports Operating Results (10-Q/A) Nov 15 2010 
Discovery Laboratories Inc. Reports Operating Results (10-Q) May 10 2010 
Discovery Laboratories Inc. Reports Operating Results (10-Q) Nov 09 2009 
Discovery Laboratories Inc. Reports Operating Results (10-Q) Aug 10 2009 
Discovery Laboratories Inc. Reports Operating Results (10-Q) May 12 2009 

More From Other Websites
DISCOVERY LABORATORIES INC /DE/ Financials Aug 21 2015
10-Q for Discovery Laboratories, Inc. Aug 12 2015
DISCOVERY LABORATORIES INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 10 2015
Discovery Labs Provides Business Update and Reports Second Quarter 2015 Financial Results Aug 10 2015
Q2 2015 Discovery Laboratories Inc Earnings Release - After Market Close Aug 10 2015
Discovery Labs to Hold Conference Call on Tuesday August 11, 2015 to Discuss Second Quarter 2015... Aug 03 2015
Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of... Jul 30 2015
DISCOVERY LABORATORIES INC /DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jul 24 2015
Discovery Labs Announces Completion of $40.25 Million Public Offering Jul 22 2015
Bucks biopharmaceutical firm wants to raise $35 million Jul 20 2015
DISCOVERY LABORATORIES INC /DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jul 17 2015
Discovery Labs Announces Pricing of $35 Million Public Offering of Common Stock, Warrants and... Jul 17 2015
Discovery Labs Announces Proposed Public Offering of Common Stock, Warrants and Pre-funded Warrants Jul 16 2015
DISCOVERY LABORATORIES INC /DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jul 09 2015
DISCOVERY LABORATORIES INC /DE/ Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a... Jul 01 2015
Discovery Labs Receives Nasdaq Notification Related to Minimum Bid Price Jul 01 2015
DISCOVERY LABORATORIES INC /DE/ Files SEC form 8-K, Submission of Matters to a Vote of Security... Jun 09 2015
Discovery Labs Announces Enrollment of First Patient in AEROSURF® Phase 2a Dose Expansion Trial May 20 2015
DISCOVERY LABORATORIES INC /DE/ Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 15 2015
Discovery Labs Announces Results of Phase 2a Clinical Trial of AEROSURF® May 14 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK